Evidence map›Paper›PMID 39234402›Full record

ArticleFrontiers in oncology2024

Case report: Metastatic

Matthew R Kroll, Cherry Au, Jessica Slostad, Trevor N Christ, Sam G Papas, Alan Tan

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Matthew R KrollDepartment of Internal Medicine, Rush University Medical Center, Chicago, IL, United States.
Cherry AuDepartment of Internal Medicine, Rush University Medical Center, Chicago, IL, United States.
Jessica SlostadDivision of Hematology, Oncology, and Cellular Therapies, Rush University Medical Center, Chicago, IL, United States.
Trevor N ChristDepartment of Pharmacy, Rush University Medical Center, Chicago, IL, United States.
Sam G PapasDivision of Surgical Oncology, Rush University Medical Center, Chicago, IL, United States.
Alan TanDivision of Hematology, Oncology, and Cellular Therapies, Rush University Medical Center, Chicago, IL, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nephroblastoma or Wilms' tumor (WT) is the most common pediatric renal malignancy but rare in adults. Treatment protocols for adults are typically extrapolated from pediatric guidelines, but there are no standard guidelines for adults due to the rarity of the disease. However, next-generation sequencing has led to new therapeutic options for adult WT patients. We present the first case to our knowledge of a recurrent adult WT treated with dual

Indexed as

BRAF/MEK inhibitionBRAF V600Eprecision oncologyrare tumorsWilms

Identifiers

PMID39234402
PMCPMC11373342

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.